Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?
Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.
Pharma & Biotech
Pharma & Biotech
Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?
Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.
Pharma & Biotech
Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.
Pharma & Biotech
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Pharma & Biotech
What D3 Bio’s dual KRAS IND clearances reveal about the next wave of targeted oncology
D3 Bio secures U.S. FDA IND clearances for two KRAS programs, advancing G12D monotherapy and G12C resistance combo trials. See what this means for oncology.
Pharma & Biotech
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.